We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+12.37%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$7.87B
AUM Growth
+$772M
Cap. Flow
-$1.35B
Cap. Flow %
-17.14%
Top 10 Hldgs %
73.35%
Holding
114
New
19
Increased
20
Reduced
44
Closed
6

Top Buys

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$93M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$34.7M
3
ACOR
Acorda Therapeutics
ACOR
+$33.7M
4
HRTX icon
Heron Therapeutics
HRTX
+$29M
5
XNPT
XENOPORT, INC.
XNPT
+$18.1M

Top Sells

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$41.4M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$35.9M
3
MDVN
MEDIVATION, INC.
MDVN
+$25.4M
4
HALO icon
Halozyme
HALO
+$8.89M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$8.88M

Sector Composition

Rank Sector Weight
1 Healthcare 48.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OSUR icon
76
OraSure Technologies
OSUR
$268M
$1.87M 0.02%
234,664
-8,803
-4% -$61.5K
RIGL icon
77
Rigel Pharmaceuticals
RIGL
$857M
$1.87M 0.02%
48,197
-1,803
-4% -$64.3K
KPTI icon
78
Karyopharm Therapeutics
KPTI
$44.5M
$1.82M 0.02%
3,940
-149
-4% -$75.5K
AUXL
79
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$1.59M 0.02%
+58,544
New +$1.55M
AKAO
80
DELISTED
Achaogen Inc
AKAO
$1.55M 0.02%
+100,000
New +$1.73M
ACHN
81
DELISTED
Achillion Pharmaceuticals
ACHN
$1.44M 0.02%
438,337
-16,663
-4% -$58.3K
ISEE
82
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.31M 0.02%
36,776
-66,264
-64% -$2.24M
CPRX
83
DELISTED
Catalyst Pharmaceutical
CPRX
$1.29M 0.02%
+569,853
New +$1.19M
TCRT icon
84
Alaunos Therapeutics
TCRT
$4.47M
$1.12M 0.01%
1,631
-64
-4% -$42.9K
RCPT
85
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$1M 0.01%
23,900
-76,100
-76% -$3.27M
FOLD
86
DELISTED
Amicus Therapeutics
FOLD
$997K 0.01%
481,697
-33,375
-6% -$83.4K
XLRN
87
DELISTED
Acceleron Pharma
XLRN
$992K 0.01%
28,765
-1,235
-4% -$55.7K
TSRO
88
DELISTED
TESARO, Inc.
TSRO
$920K 0.01%
31,218
– –
GERN icon
89
Geron
GERN
$977M
$837K 0.01%
425,981
– –
ALNY icon
90
Alnylam Pharmaceuticals
ALNY
$31.6B
$779K 0.01%
+11,600
New +$898K
ASMB icon
91
Assembly Biosciences
ASMB
$700M
$535K 0.01%
6,962
-13,302
-66% -$2.07M
QURE icon
92
uniQure
QURE
$3.36B
$477K 0.01%
+30,672
New +$489K
FPRX
93
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$390K 0.01%
19,823
– –
SLXP
94
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$375K ﹤0.01%
3,621
– –
CCXI
95
DELISTED
ChemoCentryx, Inc.
CCXI
$332K ﹤0.01%
50,000
– –
PBYI icon
96
Puma Biotechnology
PBYI
$477M
– –
-25,000
Closed -$2.59M
UTHR icon
97
United Therapeutics
UTHR
$22B
– –
-20,000
Closed -$2.26M
GWPH
98
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-94,172
Closed -$3.91M
FMI
99
DELISTED
Foundation Medicine, Inc.
FMI
– –
-20,000
Closed -$476K
MDVN
100
DELISTED
MEDIVATION, INC.
MDVN
– –
-796,662
Closed -$25.4M
1 2 3
4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2014 Portfolio in Review

As of Q1 2014, Julian Baker held 114 positions worth $7.87B, up 11% from $7.1B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Julian Baker withdrew a net $1.35B in Q1 2014, closing 6 positions and reducing 44 holdings. Its most notable exit was MEDIVATION, INC., an estimated $25.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 50% a quarter earlier.

Against the trend, Julian Baker opened a new position in Acorda Therapeutics worth $37.9M.

  • Julian Baker's largest Q1 2014 buy was Acorda Therapeutics: 8,333 shares worth $37.9M.
  • Julian Baker added most to INTERMUNE INC in Q1 2014, an estimated $93M increase.
  • Julian Baker's biggest Q1 2014 reduction was Arrowhead Research, cutting an estimated $41.4M.
  • Julian Baker fully exited MEDIVATION, INC. in Q1 2014, selling an estimated $25.4M.
  • Julian Baker's ten largest holdings make up 73% of its $7.87B portfolio in Q1 2014.
  • Julian Baker opened 19 new positions and closed 6 in Q1 2014.
  • Julian Baker's portfolio value rose 11% quarter-over-quarter to $7.87B.

Based on Baker Bros. Advisors's 13F filing for Q1 2014, filed 15 May 2014.